• metastatic/advanced hepatocellular cancer (mHCC)
• mHCC - (neo)adjuvant (NA) 3
• mHCC - 1st line (L1) 10
• mHCC - 2nd line (L2) 2
• lung cancer : non small cell (NSCLC) 5

 

• antibody–drug conjugate
• trastuzumab deruxtecan
• chemotherapy
• antifolates
• pralatrexate
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus BSC
• gene alteration target therapy
• ALK inhibitors
• alectinib
• brigatinib
• ceritinib
• crizotinib
• BRAF gene alteration targeted therapy
• BRAF inhibitor
• combined BRAF-MEK inhibitors
• trametinib plus dabrafenib
• EGFR gene alteration
• amivantamab-vmjw
• mobocertinib
• osimertinib
• KRAS gene alteration targeted therapy
• adagrasib
• sotorasib
• MET gene alteration targeted therapy
• capmatinib
• savolitinib
• tepotinib
• NTRK gene alteration targeted therapy
• entrectinib
• larotrectinib
• RET gene alteration targeted therapy
• pralsetinib
• selpercatinib
• ROS1 and TRK TKI
• repotrectinib
• HER inhibitor
• EGFR inhibitor
• afatinib based treatment
• afatinib alone
• afatinib plus BSC
• afatinib plus paclitaxel
• dacomitinib
• erlotinib based treatment
• erlotinib alone
• erlotinib followed by gemcitabine plus platin
• erlotinib plus bevacizumab
• erlotinib plus cisplatin and gemcitabine
• erlotinib plus gemcitabine
• erlotinib plus pemetrexed
• erlotinib plus SoC
• tivantinib plus erlotinib
• gefitinib based treatment
• gefitinib alone
• gefitinib plus BSC
• gefitinib plus pemetrexed plus platin
• gefitinib plus SoC
• gefitinib plus SoC (rechallenge)
• pemetrexed plus platin followed by maintenance gefitinib
• SoC followed by gefitinib
• icotinib
• naquotinib
• nimotuzumab based treatment
• nimotuzumab plus gefitinib
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• ipilimumab plus SoC
• ipilimumab followed by nivolumab
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus carboplatin plus paclitaxel
• atezolizumab plus pemetrexed and platin
• avelumab based treatment
• avelumab alone
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• durvalumab plus osimertinib
• durvalumab plus SoC
• nivolumab based treatment
• nivolumab alone
• nivolumab plus SoC
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (2mg/kg)
• pembrolizumab and pemetrexed plus platin
• pembrolizumab followed by nab-paclitaxel
• pembrolizumab plus SoC
• sintilimab based treatment
• sintillimab plus SoC
• sugemalimab based treatment
• Sugemalimab
• sugemalimab plus SoC
• Tislelizumab
• anti-TIGIT
• tiragolumab
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• pembrolizumab plus ipilimumab
• VEGF(R) inhibitor
• ramucirumab
• ramucirumab plus erlotinib
• sorafenib
• sorafenib and erlotinib
• vandetanib

• versus all
• vs chemotherapy
• vs antifolates
• vs pemetrexed
• vs non platinum-based chemotherapy
• vs alkylating agents
• vs temozolomide
• vs nucleoside analogues (pyrimidine/purine)
• vs gemcitabine
• vs taxanes
• vs docetaxel
• vs paclitaxel
• vs nab-paclitaxel
• vs topoisomerase I inhibitor
• vs irinotecan
• vs irinotecan plus platin
• vs vinca alkaloids
• vs vinorelbine
• vs vinorelbine and platin
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs docetaxel plus platin
• vs gemcitabine plus platin
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs gene alteration target therapy
• vs ALK inhibitors
• vs crizotinib
• vs EGFR gene alteration
• vs osimertinib
• vs HER inhibitor
• vs EGFR inhibitor
• vs erlotinib based treatment
• vs erlotinib alone
• vs Erlotinib plus BSC
• vs gemcitabine plus platin followed by erlotinib
• vs placebo plus erlotinib
• vs gefitinib based treatment
• vs gefitinib alone
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs atezolizumab based treatment
• vs atezolizumab plus carboplatin plus nab-paclitaxel
• vs durvalumab based treatment
• vs durvalumab alone
• vs pembrolizumab based treatment
• vs nab-paclitaxel followed by pembrolizumab
• vs pembrolizumab alone
• vs pembrolizumab (10mg/kg)
• vs pembrolizumab plus placebo
• vs pembrolizumab plus SoC
• vs non active control
• vs no additional treatment
• vs no control (uncontrolled study)
• vs placebo
• vs placebo plus BSC
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs bevacizumab plus carboplatin and paclitaxel
• vs bevacizumab plus docetaxel
• vs bevacizumab plus gemcitabine and platin
• vs placebo plus bevacizumab
• vs cabozantinib
• vs cabozantinib plus erlotinib
• vs sorafenib
• vs sorafenib and erlotinib
• vs sorafenib and gemcitabine

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)